ORG
Clinical Roundup: Cardiff, VYNE and NewAmsterdam Report Key Trial Results in Multiple Disease Areas
Cardiff Oncology; VYNE; NewAmsterdam Pharma; clinical trial updates; onvansertib; metastatic colorectal cancer; Alzheimer’s disease; BROADWAY trial; oncology; statistically significant results
FDA Misses IND Deadline for Coya’s ALS Asset, Citing Resource Constraints
FDA; Coya Therapeutics; IND application; ALS; clinical trial delay; COYA 302; resource shortage
Vinay Prasad Departs FDA Amid Conservative Criticism and Sarepta Gene Therapy Controversy
Vinay Prasad; FDA; departure; Sarepta Therapeutics; gene therapy; Duchenne muscular dystrophy; conservative criticism; CBER; drug approval controversy; Trump administration
Madrigal Pharmaceuticals Inks up to $2B Deal with CSPC for Preclinical Oral GLP-1, Plans Combination with Rezdiffra for MASH
Madrigal Pharmaceuticals; CSPC Pharmaceutical Group; GLP-1 receptor agonist; SYH2086; Rezdiffra; MASH; oral small molecule; preclinical drug; global license agreement; combination therapy; milestone payments
Teva Execs Shrug Off Pharmaceutical Tariff Threat as Turnaround Strategy Rolls Forward
Teva; tariff threat; pharmaceutical tariffs; turnaround strategy; supply chain; pivot to growth; earnings; innovative medicines; Richard Francis; operating profit margin
Jaypirca Demonstrates Superior Efficacy Over Imbruvica in BTK Inhibitor Clash for CLL/SLL
Jaypirca; Imbruvica; BTK inhibitor; chronic lymphocytic leukemia; small lymphocytic lymphoma; BRUIN CLL-314; overall response rate; progression-free survival; head-to-head trial; Eli Lilly
Merck Terminates Midstage Asset from $1.9B Pandion Acquisition over Lack of Clinical Benefit
Merck; Pandion Therapeutics; asset termination; clinical trial; lack of benefit; biotech acquisition
Novo Nordisk Appoints New CEO and Reduces 2025 Sales Guidance
Novo Nordisk; CEO change; Maziar Mike Doustdar; 2025 sales guidance cut; growth outlook; leadership transition; obesity drug competition
Novo Nordisk Names Insider Maziar Mike Doustdar as New CEO Amid Growth Challenges
Novo Nordisk; Maziar Mike Doustdar; CEO appointment; leadership change; pharmaceutical industry; growth outlook; obesity drug market; international operations
Merck & Co. Targets $3B in Cost Savings Through Restructuring, Including Job Cuts
Merck & Co.; cost-cutting; $3 billion savings; restructuring; job cuts; 2027 target; restructuring charges; R&D; manufacturing investments